当全省高质量发展大会发出"制造业与服务业协同发展"的动员令后，2月25日，广州市高质量发展大会 召开，大会主题落笔"工商并举，推动制造业与服务业深度融合、协同发展"——这既是对过去高质量发 展路径的深化，更是对"十五五"开局之年的战略定调。 拥有35个工业大类、10个千亿级服务业的广州，如何在"两业融合"中打开新空间？在大会的发言台上， 答案逐渐清晰——人工智能作为贯穿"两业融合"全过程的关键变量，让制造长出"智慧大脑"，让服务装 上"坚硬骨架"，催生"1+1>2"的化学反应。 以强基支撑 深耕"海陆空"制造业 制造业是两业融合的根基。过去一年，广州自动驾驶、智能终端、创新药械等新赛道加速布局，时尚消 费品等优势产业焕新升级，2个百亿级、42个十亿级制造业项目落地建设。这是广州的"工业家底"。 在广州开发区、黄埔区，粤芯四期项目于1月正式启动，投资额达252亿元。"继1月之后，我们乘势而 上，58个项目总投资超700亿，其中，投资、产值双双超百亿的工业项目3个。"黄埔区区长冼银崧晒出 的这份"开工清单"，彰显了工业"顶梁柱"的分量。她表示，黄埔区今年目标是规上工业总产值突破8600 亿，引进优质产业项目500 ...

Core Viewpoint - The report from交银国际 indicates a slight decrease in the proportion of domestic investors holding pharmaceutical stocks through the Hong Kong Stock Connect since the fourth quarter of last year, while foreign investment has increased, particularly in innovative drugs and leading CXO companies benefiting from demand recovery [1] Group 1: Investment Trends - Domestic investors' holdings in pharmaceutical stocks via Hong Kong Stock Connect have slightly decreased [1] - Foreign investors have increased their positions, particularly in innovative drug companies and leading CXO firms [1] Group 2: Investment Recommendations - The report suggests focusing on differentiated platforms such as small nucleic acids, long-acting formulations, invivo CAR-T, and new generation ADC/XDC, as well as disease areas like autoimmune, metabolic, and CNS [1] - The pharmaceutical sector is expected to maintain a stable upward trend this year, although short-term volatility may occur [1] Group 3: Stock Selection Criteria - Investors are advised to examine company fundamentals and valuations to identify undervalued stocks, such as 三生制药, 和黄医药, and 劲方医药, which have rich catalysts not yet reflected in their valuations [1] - CXO segment leaders, like 药明合联, are expected to benefit from a favorable downstream environment and improved financing conditions [1] - Sub-sectors such as hospitals, medical devices, and diagnostics are anticipated to see regulatory uncertainties gradually easing along with positive policy expectations [1]

（文章来源：每日经济新闻） 中信证券认为，在基本医保管理边界逐渐明晰的趋势下，商保有望成为医疗健康产业支付端的核心增 量，当前政策红利、数据资产与商业健康险产品迭代共振有望开启医疗健康产业多元化支付体系发展新 周期。下一阶段，中信证券认为商保综合服务提供商有望解决保司端人才、数据制约，打开创新药械企 业创新价值兑现面临的结构性瓶颈，进一步助推商业健康险行业边际加速发展。认为伴随商保支付渗透 率提升与数据智能驱动的控费模式成熟，具备药险资源整合能力与技术壁垒的平台型公司，有望脱颖而 出成长为行业龙头。持续建议关注以下三条投资主线：1）平台型公司赋能药险协同，开启支付体系"换 挡升级"新周期。2）创新药械——创新药械有望受益于商业健康险带来的增量支付额以及估值体系提 升；3）民营医疗终端——迎来新支付方，打开未来业绩成长空间。 ...

Core Viewpoint - The Hang Seng Healthcare Index has declined by 3.3% this week, underperforming the market, with a slight decrease in domestic investors' holdings of pharmaceutical stocks through the Hong Kong Stock Connect since the fourth quarter of last year, while foreign investment has increased [1] Group 1: Market Performance - The Hang Seng Healthcare Index has experienced a cumulative drop of 3.3% this week [1] - Domestic investors' holdings of pharmaceutical stocks via the Hong Kong Stock Connect have slightly decreased [1] - Foreign investment in the sector has increased, particularly in innovative drugs and leading CXO companies benefiting from demand recovery [1] Group 2: Investment Recommendations - The company suggests focusing on differentiated platforms such as small nucleic acids, long-acting formulations, invivo CAR-T, and new generation ADC/XDC in the pharmaceutical business development this year [1] - The sector is expected to maintain a stable upward trend this year, although short-term volatility may occur [1] - Investors are advised to examine company fundamentals and valuations to identify undervalued stocks, such as 3SBio (01530), Hutchison China MediTech (00013), and Genscript Biotech (02595) [1] - CXO segment leaders like WuXi AppTec (02268) may benefit from a favorable downstream environment and improved financing conditions [1] - Sub-sectors such as hospitals, medical devices, and diagnostics may see regulatory uncertainties easing along with positive policy expectations [1]

截至2026年1月28日 10:09，中证医药及医疗器械创新指数(931484)下跌0.45%。成分股方面涨跌互现， 片仔癀领涨1.57%，兴齐眼药上涨1.00%，新和成上涨0.80%；华兰生物领跌。医疗创新ETF(516820)最 新报价0.36元。 风险提示：基金有风险，投资需谨慎。基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资 产，但不保证本基金一定盈利，也不保证最低收益。基金管理人提醒投资人基金投资的"买者自负"原 则，在做出投资决策后，基金运营状况与基金净值变化引致的投资风险，由投资人自行负担。基金的过 往业绩及其净值高低并不预示其未来业绩表现，基金管理人管理的其他基金的业绩不构成对本基金业绩 表现的保证。投资人购买基金，既可能按其持有份额分享基金投资所产生的收益，也可能承担基金投资 所带来的损失。投资人应当认真阅读《基金合同》《招募说明书》等基金法律文件，全面认识本基金的 风险收益特征和产品特性，并根据自身的投资目的、投资期限、投资经验、资产状况等判断基金是否和 投资人的风险承受能力相适应，理性判断市场，谨慎做出投资决策。本材料中相关信息来源于基金管理 人认为可靠的公开资料，相关观点、评 ...

Core Viewpoint - Cathay Pacific Haitong continues to recommend innovative pharmaceuticals and medical devices, highlighting the high growth potential in the innovative drug sector and the gradual realization of performance in Biopharma/Biotech [1] Group 1: Investment Recommendations - The company recommends Pharma, which is expected to see a revaluation due to its value potential [1] - Biopharma/Biotech is highlighted for its innovative pipelines and performance entering a growth phase [1] - CXO and upstream pharmaceutical sectors are recommended due to their benefits from innovation and recovery in market conditions [1] Group 2: Medical Devices and Consumer Healthcare - Medical devices are recommended, particularly those benefiting from engineering talent and successful overseas expansion [1] - The consumer healthcare sector is noted for its gradual recovery [1] Group 3: Policy Support and Market Catalysts - Recent supportive policies include the National Healthcare Security Administration's release of guidelines for pricing projects related to surgical and therapeutic auxiliary services, which are expected to benefit innovative surgical projects [1] - The medical device sector is experiencing frequent catalysts, with investment opportunities in overseas expansion, brain-computer interfaces, and AI healthcare [1] Group 4: ETF and Index Information - The Cathay Pacific Medical ETF (159377) tracks the innovative pharmaceutical index (399275), which has a daily price fluctuation limit of 20% [1] - This index focuses on innovative biopharmaceuticals, including companies engaged in biotechnology, genetic engineering, and new drug development, reflecting the overall performance of related listed companies [1] - The index emphasizes high growth potential and innovation capability, aiming to represent the development trends in the relevant industry [1]

报告提出，科技创新加快引领新质生产力发展，持续提升国际科技创新中心能级，强化原创性引领性科 技攻关，210项关键核心技术获得突破，北京连续9年稳居自然指数—科研城市全球榜首，新增两院院士 占全国近一半。加速发展高精尖产业，集成电路产业规模增长超20%，新能源汽车年产量近70万辆，34 款创新药械获批上市，国际医药创新公园新引入8家跨国药企，全市国家级高新技术企业数量突破3万 家。 北京商报讯（记者 程靓）1月25日上午，北京市第十六届人民代表大会第四次会议在北京会议中心开 幕。市长殷勇作政府工作报告。 ...

Core Viewpoint - The "15th Five-Year Plan" for Shanghai aims to accelerate the construction of a world-class socialist modern international metropolis, emphasizing the importance of the "Five Centers" in enhancing the city's global influence and competitiveness [1][2]. Group 1: Five Centers Development - The "Five Centers" are crucial for Shanghai's modernization, focusing on enhancing the city's capabilities and core competitiveness through innovation and coordinated development [1][2]. - The plan emphasizes the integration of economic, financial, trade, shipping, and technological innovation functions to strengthen global resource allocation capabilities [2]. Group 2: Modern Industrial System - The proposal outlines the construction of a "2+3+6+6" modern industrial system, with advanced manufacturing as the backbone, aiming to create world-class high-end industrial clusters and promote the "Shanghai Manufacturing" brand [2]. - The focus will be on the digital and green transformation of traditional industries, leveraging artificial intelligence to enhance production processes and operational efficiency [3]. Group 3: Leading Industries - Shanghai will accelerate the development of three leading industries, including integrated circuit equipment, innovative pharmaceuticals, and artificial intelligence, to achieve breakthroughs across the entire industrial chain [3]. - The plan highlights the importance of agile layout in key areas such as quantum technology, brain-machine interfaces, and biomanufacturing to foster future growth [3].

Core Viewpoint - The "15th Five-Year Plan" for Shanghai aims to accelerate the construction of a world-influential socialist modern international metropolis, emphasizing the importance of the "Five Centers" in achieving national strategies and ensuring national security [1][2]. Group 1: Five Centers Development - The "Five Centers" are crucial for Shanghai's modernization, focusing on enhancing the city's capabilities and core competitiveness through innovation and coordinated development [2][3]. - The plan outlines systematic deployments to elevate Shanghai's status as an international economic center, enhance its international financial competitiveness, upgrade its international trade center, build a leading global shipping center, and strengthen its role as an international technology innovation hub [2][3]. Group 2: Modern Industrial System - The proposal emphasizes constructing a "2+3+6+6" modern industrial system, with advanced manufacturing as the backbone, aiming to create world-class high-end industrial clusters and promote the "Shanghai Manufacturing" brand [4]. - Traditional industries are encouraged to undergo digital and green transformation, leveraging artificial intelligence to enhance design, optimize production processes, and improve operational efficiency [4]. - The plan highlights the development of three leading industries over the next five years, focusing on integrated circuit equipment, innovative pharmaceuticals, and comprehensive advancements in artificial intelligence [4].

Core Insights - The innovative pharmaceutical and medical device market is a crucial part of China's healthcare industry, experiencing rapid growth despite its late development compared to developed economies [1][6] - By 2025, the number of approved innovative drugs reached 69, and innovative medical devices reached 73, marking a historical high in approvals [1][7] - The market size for innovative drugs and devices is projected to grow from 162 billion yuan in 2025 to 440 billion yuan by 2035, driven by demographic changes, clinical needs, and favorable policies [1][7] Group 1: Market Overview - The innovative drug and device market in China is expected to see significant growth, with projections of 2,186 billion yuan in 2026 and 4,102 billion yuan by 2030 [1][7] - The number of innovative drugs approved for market entry in 2024 is 48, while 65 innovative medical devices are expected to be approved [1][6] - The market is characterized by a high number of new drug approvals, with China ranking second globally in the number of drugs under development [1][6] Group 2: Payment Structure - In 2024, personal cash expenditure on innovative drugs and devices is estimated at 786 billion yuan, accounting for 49% of total spending, while insurance funds contribute approximately 710 billion yuan (44%) [7] - By 2035, it is anticipated that personal cash expenditure will decrease to 20%, while insurance fund contributions will rise to 36% [7] Group 3: Industry Chain - The innovative drug and device industry chain includes upstream components such as raw materials and research services, midstream research and manufacturing, and downstream distribution and application [8][9] - The government has been enhancing the policy framework to support the entire chain from research to application, facilitating faster approvals and market entry [9] Group 4: Future Outlook - The innovative drug and device industry in China is poised for opportunities due to ongoing national strategic support, the integration of new technologies like AI, and improved payment environments [11] - Challenges include insufficient global clinical capabilities and geopolitical factors affecting international expansion [11]